Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Aug 4, 2011


Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid

Patent Number: 7,989,612

Filed: Aug. 4, 2006

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent's abstract states, “concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules ... capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.”

Title: Composition for Suppressing Expression of Target Gene

Application Number: 20110182980

Filed: Jan. 31, 2011

Lead Inventor: Nobuhiro Yagi, Kyowa Hakko Kirin

The invention, the patent application's abstract states, comprises “a composition for suppressing expression of a target gene, and the like.” The composition is made up of an “RNA-encapsulated liposome, wherein the RNA contains a sequence consisting of 15 to 30 contiguous bases of a target gene mRNA and a base sequence complementary to the [target mRNA] ... and the lipid particle ... capable of reaching a tissue or an organ containing an expression site of the target gene.”

Title: Polyamides for Nucleic Acid Delivery

Application Number: 20110183417

Filed: March 10, 2011

Inventor: Theresa Reineke, Virginia Tech

The invention “provides a new class of non-viral transduction vectors that can be used for both in vivo and in vitro applications,” the patent application's abstract states. “In particular, these vectors can be used for gene transfer applications. These new gene transduction vectors can achieve transfer efficiencies far greater [than] commercially available polymeric and liposomal gene transfer vectors while maintaining little or no toxicity in vitro. Their low in vitro toxicity makes them ideal candidates for in vivo use.”

The invention also provides “a gene-transfer vector that has comparable efficiency to a viral vector without the potential for a life-threatening immune response. Furthermore, the unique polycationic structure of these polymers associates with many suitable biologically active molecules, including oligonucleotides and polypeptides and other compounds that pose multiple cationic sites. The polymer can act as a delivery vehicle for the associated biologically active molecule, in vivo or in vitro, to the cells of interest for the biologically active molecule. Complexes according to the invention or portions thereof can comprise a cellular delivery molecule or agent that can facilitate the translocation of the complex or portion thereof into cells.”

Title: Inflammatory Genes and microRNA-21 as Biomarkers for Colon Cancer Prognosis

Application Number: 20110183859

Filed: Sept. 25, 2009

Lead Inventor: Curtis Harris, Health and Human Services

The invention comprises “methods for detecting a more aggressive form of a colon adenocarcinoma in a subject, thereby predicting the prognosis of the subject,” according to the patent application's abstract. “The methods generally include determining an inflammatory gene expression signature in the colon adenocarcinoma and/or the adjacent non-cancerous tissue. … In some embodiments, the method further includes detecting expression of microRNA-21 in the colon adenocarcinoma. Altered expression of one or more of the inflammatory genes or miR-21 indicates the prognosis of the subject. Also provided are arrays consisting essentially of probes specific for PRG1, ANXA1, IL-17a, IL-23a, FOXP3, HLA-DRA, IL-10, CD68, IL-12a and miR-21.”

Title: Silencing and RIG-1 Activation by Dual Function Oligonucleotides

Application Number: 20110184045

Filed: June 30, 2009

Inventor: Gunther Hartmann, University Hospital Bonn

The invention, the patent application's abstract states, comprises “a method of determining whether a double-stranded RNA silences gene expression in a cell in vivo by an RNA interference mechanism by performing 5'-rapid amplification of cDNA ends to detect the cleavage site of the mRNA in the RNA sample.”

Title: Compositions and Methods for Inhibiting Expression of GSK-3 Genes

Application Number: 20110184046

Filed: July 13, 2009

Lead Inventor: Dinah Sah, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid targeting glycogen synthase kinase-3 and methods of using the dsRNA to inhibit expression of GSK-3,” according to the patent application's abstract.

Title: RNAi Modulation of SCAP and Therapeutic Uses Thereof

Application Number: 20110184047

Filed: April 5, 2011

Lead Inventor: Juergen Soutschek, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a SCAP gene comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19 [to] 25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene,” the patent application's abstract states. “The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.”

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.